Introduction
Human epidermal growth factor receptor 2 (Her-2) status is of a predictive and prognostic importance in breast carcinoma. Overexpression of Her-2 and/or amplification of Her-2/neu gene are associated with poorer prognosis [1] . Her-2 testing is essential in selecting patients for treatment with trastuzumab and other Her-2-targeted therapies. Her-2 positivity appears to be associated with relative resistance to endocrine therapies [2] . Her-2 status also appears to be predictive for response to chemotherapeutic agents [3] [4] [5] .
Dual-probe fluorescence in situ hybridization (D-FISH) is an established method to determine the gene amplification status of Her-2. The number of Her-2 signals, the number of signals determined by a control probe to the centromeric portion of chromosome 17 (CEP17), and their ratio were the three parameters for Her-2 FISH interpretation [6] . In 2007, a guideline was developed by the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) to improve the accuracy of Her-2 testing in invasive breast cancer (BCa). For D-FISH, Her-2 amplification was defined by Her-2/CEP17 ratio, and a tumor with Her-2/CEP17 ratio of 1.8-2.2 was classified as equivocal according to the 2007 guidelines [7] . In 2013, the ASCO/ CAP guidelines were updated. For D-FISH, the most notable change was that Her-2 interpretation also took the average number of Her-2 signals per cell into account. The cutoff Her-2/CEP17 ratio was defined as 2.0. Cases with Her-2/CEP17 ratio C2.0 or cases with Her-2/CEP17 ratio \2.0 and the average number of Her-2 signals per cell C6 was classified as positive; cases with Her-2/CEP17 ratio \2.0 and the average number of Her-2 signals per cell C4 and \6 were classified as equivocal [8] .
Although the 2013 ASCO/CAP guidelines significantly improved the detection rate of Her-2 amplification, equivocal results have increased significantly, which poses a dilemma for clinical management. In this study, we compared the Her-2 D-FISH results based on the 2013 and 2007 ASCO/CAP guidelines, and analyzed the clinicopathologic features of cases with equivocal results by the 2013 ASCO/CAP guidelines.
Materials and methods

Human BCa specimens
At our institution, all invasive breast carcinomas are routinely tested for Her-2 expression by immunohistochemistry (IHC), and cases showing equivocal (2?) staining by IHC require reflex testing by Her-2 D-FISH. Her-2 D-FISH was also performed on some Her-2-negative (1?) or Her-2-positive (3?) cases by IHC to further verify Her-2 status per specific requests by treating physicians for various reasons. We retrieved all invasive breast carcinoma specimens with Her-2 D-FISH testing at our institution from March 2014 to June 2015. Most of the cases were Her-2 equivocal (2?) by IHC. In order to gain a better understanding of correlation between Her-2 IHC and FISH results, we also performed Her-2 D-FISH on 255 consecutive cases of invasive BCa from all patients who underwent surgical excision from January to February 2014 at our institution regardless of Her-2 results by IHC. Tissue sections were independently reviewed by two pathologists to confirm the diagnosis using the WHO criteria and the histologic grade of invasive carcinoma. Patients who received neoadjuvant chemotherapy were excluded.
Immunohistochemistry (IHC)
IHC for Her-2 was performed with BenchMark XT Automated IHC/ISH slide staining system (VENTANA) using anti-Her-2/neu antibody (clone number 4B5, VENTANA). Each case was scored independently according to the 2013 ASCO/CAP Guidelines [8] by two pathologists. IHC for estrogen receptor a (ERa) was performed using monoclonal rabbit anti-human ERa antibody (clone # EP1, Dako) and evaluated by two pathologists independently according to the ASCO/CAP guidelines [9] . IHC for Ki67 was performed using monoclonal rabbit anti-human Ki67 antibody (clone # SP6, Lab Vision Corporation) and evaluated by two pathologists independently recording the proportion of positive tumor cells [10, 11] .
Her-2 D-FISH
Four-micrometer deparaffinized tissue sections were used for Her-2 gene amplification testing using the US Food and Drug Administration-approved Vysis PathVysion probe set (Abbott Diagnostics), according to the protocol recommended by the manufacturer. The entire slides were scanned using a NIKON 90i fluorescence microscope (NIKON, Japan) with a triple-pass filter band (DAPI/green/orange). A total of 20 cells of invasive carcinoma with optimal nuclear signals were randomly selected in 2-4 separate fields for evaluation. Signals of Her-2 and CEP17 were counted manually according to the specification of the kit. Her-2 gene amplification status of each case was scored according to the 2007 [7] and 2013 [8] ASCO/CAP guidelines, respectively. In cases with equivocal results, a repeat counting of additional 20 cells in another 2-4 separate fields was performed. 
Statistic analysis
All analyses were performed using SPSS software (version 13.0). The agreement between the two analyses was analyzed using kappa test, and the discrepancy significance was analyzed using 2-sided Mcnemar test. ERa status, Ki67 index, histological grade, lymph node status, and pTNM stage between two groups were compared using nonparametric Mann-Whitney U test. ERa status and Ki67 index of three or more groups were compared using the KruskalWallis test. Histological grade, lymph node status, and pTNM stage of three or more groups were compared using the Jonckheere-Terpstra test. The correlation between equivocal D-FISH results and Her-2 IHC results was analyzed using nonparametric spearman correlation test. ERa status, Ki67 index, and histological grade of these invasive BCas with Her-2-equivocal results were compared among the Her-2 IHC 1?, 2?, and 3? groups, and no significant differences were identified (P = 0.587, P = 0.547, and P = 0.401, respectively). However, in the Her-2 IHC 1? and 2? subgroups, their Ki67 index (for IHC 1?, P = 0.002; for IHC 2?, P \ 0.001) and histological grade (for IHC 1?, P = 0.022; for IHC 2?, P \ 0.001) were significantly higher than those with Her-2-negative results by D-FISH, while their ERa expression was significantly lower (for IHC 1?, P = 0.043; for IHC 2?, P = 0.015). (Table 2) The positive rate by Her-2 D-FISH according to the 2013 ASCO/CAP guidelines was significantly higher than that by the 2007 ASCO/CAP guidelines (21.6 versus 17.6 %, P = 0.002). The equivocal rate by Her-2 D-FISH was also significantly higher according to the 2013 ASCO/CAP guidelines (12.9 versus 2.4 %, P \ 0.001). There was no agreement between these two interpretation methods (P = 0.132). Table 3 ). In addition, the average number of Her-2 signals per cell in the 17 LCP cases were significantly higher than that in the 33 Her-2 D-FISH-equivocal cases (P = 0.025 by Mann-Whitney U Test), while the average number of CEP17 signals in LCP were significantly lower than that in Her-2 D-FISHequivocal cases (P \ 0.001 by Mann-Whitney U Test). There was no agreement between the 87 cases of Her-2 Table 4 ). The Her-2 statuses by IHC in Her-2 D-FISH-equivocal group were not significantly different from those in Her-2 D-FISH-negative group (P = 0.854 by Mann-Whitney U Test, Fig. 2 ), while it was significantly lower than those in Her-2 D-FISH-positive group (P \ 0.001 by MannWhitney U Test, Fig. 2 ).
Results
Analysis of invasive
Clinicopathologic characteristics of the consecutive cases with Her-2-equivocal results by D-FISH by the 2013 ASCO/CAP guidelines
We compared the ERa status, Ki67 index, histological grade, pTNM stage, and lymph node status of the consecutive invasive BCa cases with Her-2-equivocal results by D-FISH in Her-2 0, 1?, and 2? groups, and no significant differences were identified among them (P = 0.430, P = 0.535, P = 0.829, P = 0.499, and P = 0.460, respectively). Only one of the 35 Her-2 IHC 3? cases was equivocal by D-FISH, which was not included in the analysis. Meanwhile, the Ki67 index, histological grade, and lymph node metastasis status of the patients with Her-2-equivocal results by D-FISH were significantly higher than those with Her-2 D-FISH-negative results, while ERa expression was significantly lower (Fig. 3) .
Reproducibility of the equivocal results
For the 33 cases identified as equivocal by D-FISH by the 2013 ASCO/CAP guidelines, the test was repeated in each case at alternative tissue samples (a different block of the primary tumor or the lymph node metastasis). Thirty-two of the 33 cases remained equivocal. One case became negative when tested in an alternative block, and then equivocal again in the third specimen.
Discussion
In our experience, when using the 2013 ASCO/CAP guidelines, the positive rate by Her-2 D-FISH was significantly higher compared to that using the 2007 ASCO/CAP guidelines, which may identify that more patients potentially benefit from Her-2-targeted drugs. Several recent studies reported similar results [12] [13] [14] [15] and Her-2/CEP17 ratio \2.0. In the group of 255 consecutive cases, the positive rate of D-FISH detection was similarly increased from 17.6 to 21.6 %, and 8 of 10 additional positive cases were with Her-2 signals per cell C6 and Her-2/CEP17 ratio \2.0. Our data suggest that the increase in Her-2 D-FISH-positive rate according to the 2013 ASCO/CAP guidelines was mainly due to the reclassification of cases with Her-2 signals per cell C6 and Her-2/CEP17 ratio \2.0. As per the ASCO/CAP 2007 guidelines, a tumor with Her-2/CEP17 ratio of 1.8-2.2 was classified as equivocal by D-FISH assay. However, the 2013 ASCO/CAP guidelines change the criteria for D-FISH-equivocal cases into tumor with Her-2/CEP17 ratio \2.0 and the average number of Her-2 signals per cell C4 but \6. The difference in the guidelines regarding Her-2 D-FISH-equivocal cases is obvious. Here, we used the kappa test to analyze the concordance of the equivocal results read by different criteria. It was found that there was no concordance in the equivocal results, confirming the above impression. Equivocal results have increased significantly since the adoption of the 2013 ASCO/CAP guidelines for D-FISH, which poses a dilemma for making treatment decisions. In our study, the equivocal cases by D-FISH accounted for 12.9 % in the group of 255 consecutive BCa and 9.5 % in 1266 Her-2 IHC 2? cases. A recent study also showed that the percentage of Her-2 D-FISH-equivocal cases was as high as 9.4 % according to the ASCO/CAP 2013 guidelines [16] , which was similar to our results. Several other studies also demonstrated a significant increase in the D-FISH-equivocal cases after the ASCO/CAP 2013 guideline update [12, 14, 15, 17, 18] . In addition, our assay revealed the interpretation of D-FISHequivocal results with good reproducibility. In our view, the following findings are worth emphasizing: First, the distribution of equivocal cases by Her-2 D-FISH did not correlate with Her-2 status by IHC. Second, there was no equivocality concordance between IHC and D-FISH assays. Third, Her-2 expression by IHC in Her-2 D-FISH-equivocal group was not significantly different from that in Her-2 D-FISH-negative group, while significantly lower than that in Her-2 D-FISH-positive group. These results suggest that her-2 D-FISH equivocality do not reflect Her-2 protein overexpression. Since trastuzumab and the antibody-drug conjugate adotrastuzumab emtansine [T-DM1] [19] target the Her-2 protein over-expressed cells, we consider D-FISHequivocal cases are compatible with D-FISH-negative cases with regard to the targeted therapy, and may not benefit from these treatments.
In Her-2 D-FISH analysis, Her-2/CEP17 ratio C2.0 and the average number of Her-2 signals per cell C4 and \6 are classified as gene amplified according to the 2013 ASCO/CAP guidelines. However, the clinical significance and the therapeutic correlation of these BCas with low gene copy numbers are not well studied yet. We defined the group as ''low Her-2 copy positive'' (LCP) tumor and further explored it. The distribution of LCP cases was positively correlated with the Her-2 status by IHC, while that of D-FISH-equivocal cases was not. The higher average number of Her-2 signals may partly contribute to the positive correlation between Her-2 protein expression and the occurrence of LCP; however, other factors that upregulate Her-2 expression cannot be excluded. Although the increase of the CEP17 copy numbers in D-FISHequivocal cases do not frequently represent Chromosome 17 polysomy [20] , we speculated that amplified Her-2 gene may be linked to CEP17 and limit its expression. However, in LCP, the amplified regions are more accurate, and hence the Her-2 gene is easily expressed. D-FISH could identify more patients who have the potential to benefit from Her-2-targeted drugs than single-probe FISH could. In Her-2 single-probe FISH, the cases with average Her-2 copy number C4.0 and \6.0 signals per cell were classified as equivocal per the 2013 ASCO/CAP guidelines that actually include D-FISH-equivocal cases and LCP cases.
Although we do not have outcome data pertinent to the prognosis of Her-2 D-FISH-equivocal patients who received trastuzumab with those who did not, our results questioned the benefit of trastuzumab in these patients in receptor alpha, and tumor protein p53 genes instead of CEP17 representing chromosome 17 are an effective way to determine the true Her-2 amplification status in patients with polysomy 17 [20] . However, a recent study suggested that this strategy may cause over-grading of Her-2 status in tumors [15] . As mentioned earlier, since the therapeutic targets of trastuzumab and the antibody-drug conjugate adotrastuzumab emtansine [T-DM1] [19] are the Her-2 protein over-expressed cells, it is reasonable to suspect that the findings on genome level or transcriptional level including D-FISH may not completely override the Her-2 immunohistochemical results. Although Her-2 gene amplification is highly correlated with Her-2 protein overexpression in BCa cells, complex factors in regulating gene expression on transcriptional and translational level can not be ignored, especially in D-FISH-equivocal cases. In trial N9831, the hazard ratio was 1.11 (95 % CI 0.36-3.43) in the 219 cases that had a Her-2/CEP17 ratio C2, but were IHC B2?, suggesting an apparent lack of a disease-free survival benefit from trastuzumab [8] . Although some cases with Her-2 overexpression but do not reach IHC 3 ? may not have any detectable Her-2 gene amplification, they may benefit from trastuzumab therapy. It is therefore meaningful to establish a supplemental scoring method for IHC 2? that will separate patients who may benefit from trastuzumab from those who may not. Different Her-2-targeting drugs may involve different mechanisms, such as pertuzumab inhibits the dimerization of Her-2 with other human epidermal growth factor receptors, while lapatinib, a dual tyrosine kinase inhibitor, interrupts the Her-2/neu and epidermal growth factor receptor pathways. These drugs target Her-2 down-stream signaling instead of Her-2 protein expression cells, in which accurate assessment of the Her-2 gene amplification status may be important, especially for those patients with Her-2 equivocality by both IHC and D-FISH.
Compared with Her-2-negative cases, Her-2 D-FISHequivocal cases were significantly associated with some worse prognostic factors, such as higher Ki67 index, higher histological grade, more frequent lymph node metastasis, and lower ERa expression.
In summary, this study identifies that the 2013 new guidelines significantly improves the detection rate of Her-2 amplification in BCa, while significantly increasing the number of equivocal results. The Her-2 D-FISH equivocality does not correlate with Her-2 overexpression, although it is associated with worse prognostic factors. Whether the Her-2 D-FISH-equivocal cases are of independent clinical significance or whether they may benefit from Her-2-targeted therapies warrants further investigation.
